
|Videos|January 11, 2023
2022 Society of Urologic Cancer Annual Meeting recap - SUO/YUO research highlight
Author(s)Urology Times staff
“The takeaway from that talk was that it's critically important to review drug plan options, particularly if the patient's on a high-cost drug,” says Kelly L. Stratton, MD, FACS.
Advertisement
In this video, Kelly L. Stratton, MD, FACS, recaps a presentation from the 2022 Society of Urologic Oncology Annual Meeting Young Urologic Oncologists Program regarding cost savings for prostate cancer treatments. Stratton is an assistant professor of urologic oncology at the University of Oklahoma, Oklahoma City.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












